US Bancorp DE Takes $42,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

US Bancorp DE bought a new stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,658 shares of the company’s stock, valued at approximately $42,000.

Other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC bought a new position in shares of Entrada Therapeutics in the second quarter valued at approximately $636,000. The Manufacturers Life Insurance Company grew its holdings in shares of Entrada Therapeutics by 3.9% in the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after acquiring an additional 2,146 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Entrada Therapeutics in the first quarter valued at approximately $79,000. Vanguard Group Inc. grew its holdings in shares of Entrada Therapeutics by 1.3% in the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after acquiring an additional 13,742 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Entrada Therapeutics by 87.2% during the second quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company’s stock valued at $394,000 after purchasing an additional 12,868 shares during the period. 86.39% of the stock is owned by institutional investors.

Entrada Therapeutics Trading Down 6.2 %

Shares of NASDAQ TRDA opened at $17.85 on Monday. The firm has a market cap of $667.95 million, a price-to-earnings ratio of 11.23 and a beta of -0.26. The stock has a fifty day simple moving average of $16.76 and a two-hundred day simple moving average of $15.94. Entrada Therapeutics, Inc. has a 1-year low of $10.75 and a 1-year high of $20.49.

Insiders Place Their Bets

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 2,642 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the sale, the insider now owns 183,816 shares in the company, valued at $2,773,783.44. This represents a 1.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kory James Wentworth sold 8,637 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $19.98, for a total value of $172,567.26. Following the sale, the chief financial officer now owns 73,849 shares in the company, valued at approximately $1,475,503.02. This represents a 10.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,933 shares of company stock worth $410,816 over the last 90 days. Corporate insiders own 7.59% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on TRDA. HC Wainwright increased their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Oppenheimer increased their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.